{"id":"optimized-background-regimen","safety":{"commonSideEffects":[]},"_chembl":{"chemblId":"CHEMBL388560","moleculeType":"Small molecule","molecularWeight":"304.35"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"This is a standardized combination antiretroviral therapy backbone used in clinical trials with leronlimab, typically consisting of nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs) and other agents selected to provide optimal viral suppression while allowing assessment of leronlimab's additional benefit. The regimen is tailored to individual patient resistance profiles and treatment history.","oneSentence":"An optimized antiretroviral background regimen designed to enhance the efficacy of leronlimab (a CCR5 antagonist) in HIV treatment.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T01:24:33.871Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"HIV-1 infection (as background regimen component in clinical trials)"}]},"trialDetails":[{"nctId":"NCT05586230","phase":"PHASE1","title":"Study of a Single Dose of Pretomanid Added to an Optimized Background Regimen in Children With Rifampicin-Resistant Tuberculosis","status":"RECRUITING","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2023-10-03","conditions":"Tuberculosis, Rifampicin Resistant Tuberculosis","enrollment":72},{"nctId":"NCT04150068","phase":"PHASE2, PHASE3","title":"Study to Evaluate the Safety and Efficacy of Lenacapavir (GS-6207) in Combination With an Optimized Background Regimen (OBR) in Heavily Treatment Experienced Participants Living With HIV-1 Infection With Multidrug Resistance","status":"ACTIVE_NOT_RECRUITING","sponsor":"Gilead Sciences","startDate":"2019-11-21","conditions":"HIV-1-infection","enrollment":72},{"nctId":"NCT06749054","phase":"PHASE2","title":"Evaluation of Long-Acting Lenacapavir for the Treatment of HIV-1 in Treatment-experienced Adolescents and Children","status":"RECRUITING","sponsor":"Gilead Sciences","startDate":"2025-03-26","conditions":"HIV-1-infection","enrollment":12},{"nctId":"NCT03141060","phase":"PHASE1, PHASE2","title":"Evaluating the Pharmacokinetics, Safety, and Tolerability of Delamanid in Combination With Optimized Multidrug Background Regimen (OBR) for Multidrug-Resistant Tuberculosis (MDR-TB) in HIV-Infected and HIV-Uninfected Children With MDR-TB","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2018-01-30","conditions":"Tuberculosis, HIV Infections","enrollment":37},{"nctId":"NCT06799338","phase":"","title":"Real World Use of Lenacapavir, as an add-on to an Optimized Background Regimen in France","status":"RECRUITING","sponsor":"Centre de Recherches et d'Etude sur la Pathologie Tropicale et le Sida","startDate":"2025-03-03","conditions":"HIV I Infection","enrollment":80},{"nctId":"NCT05327803","phase":"PHASE2, PHASE3","title":"Study of Epetraborole in Patients With Treatment-refractory MAC Lung Disease","status":"TERMINATED","sponsor":"AN2 Therapeutics, Inc","startDate":"2022-05-20","conditions":"MAC Lung Disease, Treatment Refractory MAC Lung Disease","enrollment":177},{"nctId":"NCT00056641","phase":"PHASE2","title":"Dual Boosted - Protease Inhibitor (PI) Pharmacokinetics (PK) Trial (Tipranavir / Ritonavir) in Highly Treatment-experienced HIV-1 Infected Patients","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2003-02-18","conditions":"HIV Infections","enrollment":328},{"nctId":"NCT01918397","phase":"PHASE2","title":"Efficacy and Safety of Levofloxacin for the Treatment of MDR-TB","status":"COMPLETED","sponsor":"Boston University","startDate":"2015-01","conditions":"Tuberculosis, Multidrug-Resistant","enrollment":111},{"nctId":"NCT03164447","phase":"PHASE2","title":"UB-421 Combine With Optimized Background Therapy Regimen in Multi-Drug Resistant HIV-1 Infection Patients","status":"UNKNOWN","sponsor":"United BioPharma","startDate":"2023-12","conditions":"HIV-1 Infection","enrollment":10},{"nctId":"NCT04406727","phase":"PHASE3","title":"UB-421 in Combination With Optimized Background Regimen in Patients With Multi-drug Resistant HIV-1 Infection","status":"NOT_YET_RECRUITING","sponsor":"United BioPharma","startDate":"2023-12-01","conditions":"HIV-1 Infection","enrollment":50},{"nctId":"NCT02483078","phase":"PHASE2, PHASE3","title":"Randomized, Double-Blind, Placebo-Controlled Trial, Followed by Single-Arm Treatment of PRO 140","status":"COMPLETED","sponsor":"CytoDyn, Inc.","startDate":"2015-10","conditions":"HIV","enrollment":52},{"nctId":"NCT00665561","phase":"","title":"Prospective Observational Epidemiologic Study of Maraviroc's Safety","status":"COMPLETED","sponsor":"ViiV Healthcare","startDate":"2008-03-31","conditions":"Human Immunodeficiency Virus","enrollment":2500},{"nctId":"NCT00685360","phase":"PHASE2","title":"A Trial to Evaluate OPC 67683 in Participants With Pulmonary Sputum Culture-positive, Multidrug-resistant Tuberculosis (TB)","status":"COMPLETED","sponsor":"Otsuka Pharmaceutical Development & Commercialization, Inc.","startDate":"2008-05-08","conditions":"Tuberculosis, Pulmonary, Tuberculosis, Multidrug Resistant, Extensively Drug-Resistant Tuberculosis","enrollment":481},{"nctId":"NCT01131351","phase":"PHASE2","title":"Safety and Pharmacokinetics (PK) in Multidrug-Resistant (MDR) Refractive Tuberculosis","status":"TERMINATED","sponsor":"Otsuka Pharmaceutical Development & Commercialization, Inc.","startDate":"2010-02-19","conditions":"Tuberculosis","enrollment":10},{"nctId":"NCT00515827","phase":"PHASE2","title":"Effect of Addition of Raltegravir (MK-0518) to PI- or NNRTI-Based ART Regimens in HIV Infected Subjects With Undetectable Viral Load","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2007-11","conditions":"HIV Infections","enrollment":53},{"nctId":"NCT01504841","phase":"PHASE1, PHASE2","title":"Evaluating the Safety and Tolerability of Etravirine in HIV-1 Infected Infants and Children","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2013-03-14","conditions":"HIV Infections","enrollment":26},{"nctId":"NCT02573350","phase":"PHASE2","title":"A Trial to Evaluate Safety, Tolerability, and Efficacy of Orally Administered OPC-67683","status":"COMPLETED","sponsor":"Otsuka Pharmaceutical Development & Commercialization, Inc.","startDate":"2009-03-26","conditions":"Tuberculosis, Multidrug-Resistant","enrollment":213},{"nctId":"NCT00243230","phase":"PHASE2","title":"Vicriviroc (SCH 417690) in Combination Treatment With Optimized ART Regimen in Experienced Participants (VICTOR-E1) (MK-7690-020/P03672)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2005-09-19","conditions":"HIV Infections","enrollment":116},{"nctId":"NCT02707861","phase":"PHASE3","title":"Ibalizumab Plus Optimized Background Regimen in Treatment-Experienced Patients With Multi-Drug Resistant HIV-1","status":"COMPLETED","sponsor":"TaiMed Biologics Inc.","startDate":"2016-03","conditions":"HIV","enrollment":79},{"nctId":"NCT01859923","phase":"PHASE2","title":"A 6-Month Safety, Efficacy, and Pharmacokinetic (PK) Trial of Delamanid in Pediatric Participants With Multidrug Resistant Tuberculosis (MDR-TB)","status":"COMPLETED","sponsor":"Otsuka Pharmaceutical Development & Commercialization, Inc.","startDate":"2013-07-20","conditions":"Multidrug Resistant Tuberculosis","enrollment":37},{"nctId":"NCT02475629","phase":"PHASE3","title":"Ibalizumab Plus Optimized Background Regimen in Patient With Multi-Drug Resistant HIV","status":"COMPLETED","sponsor":"TaiMed Biologics Inc.","startDate":"2015-08","conditions":"HIV","enrollment":40},{"nctId":"NCT00197145","phase":"PHASE3","title":"Study Of Chemokine Coreceptor 5 (CCR5) Antagonist GW873140 In R5-Tropic Treatment-Experienced HIV-Infected Subjects","status":"TERMINATED","sponsor":"ViiV Healthcare","startDate":"2005-07-21","conditions":"Infection, Human Immunodeficiency Virus I","enrollment":24},{"nctId":"NCT01056393","phase":"PHASE2","title":"Investigator-Sponsored Protocol - Continued Use of Ibalizumab","status":"COMPLETED","sponsor":"Kaiser Permanente","startDate":"2009-11","conditions":"HIV Infections","enrollment":5},{"nctId":"NCT01568892","phase":"PHASE3","title":"Study Assessing Dolutegravir in HIV-1 Infected Subjects With Virus Resistant to Raltegravir and/or Elivitegravir","status":"COMPLETED","sponsor":"ViiV Healthcare","startDate":"2012-04-18","conditions":"HIV Infections","enrollment":30},{"nctId":"NCT01856634","phase":"PHASE1","title":"Pharmacokinetic and Safety Trial to Determine the Appropriate Dose for Pediatric Patients With Multidrug Resistant Tuberculosis","status":"COMPLETED","sponsor":"Otsuka Pharmaceutical Development & Commercialization, Inc.","startDate":"2013-06-14","conditions":"Multidrug Resistant Tuberculosis, Pediatric","enrollment":37},{"nctId":"NCT02733419","phase":"PHASE3","title":"Efficacy, and Safety Study of Optimized Background Antiretroviral Regimen (OB) in Combination With Enfuvirtide in the Treatment-Experienced Participants With Human Immunodeficiency Virus-1 (HIV-1) Infection","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2004-12","conditions":"HIV Infections","enrollment":84},{"nctId":"NCT00950859","phase":"PHASE2","title":"A Pilot Study Assessing the Integrase Inhibitor GSK1349572 in HIV-infected Persons With Virus Resistant to Raltegravir","status":"COMPLETED","sponsor":"ViiV Healthcare","startDate":"2009-08","conditions":"Infection, Human Immunodeficiency Virus","enrollment":51},{"nctId":"NCT00352053","phase":"PHASE3","title":"Safety and Efficacy of Tenofovir DF in HIV-1 Infected Adolescents Failing Their Current Antiretroviral Therapy","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2006-06","conditions":"HIV Infections","enrollment":87},{"nctId":"NCT00665847","phase":"PHASE2","title":"TMC125-TiDP35-C213: Safety and Antiviral Activity of Etravirine (TMC125) in Treatment-Experienced, HIV Infected Children and Adolescents","status":"COMPLETED","sponsor":"Tibotec Pharmaceuticals, Ireland","startDate":"2008-11","conditions":"HIV-1","enrollment":103},{"nctId":"NCT00632073","phase":"PHASE1","title":"Effect of Vicriviroc on HIV Ribonucleic Acid (RNA) Levels in Cerebrospinal Fluid (Study P05241)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2008-03","conditions":"HIV Infections","enrollment":13},{"nctId":"NCT00615134","phase":"PHASE2","title":"INNOVE Study: A Study of 3 Months Induction With Fuzeon (Enfuvirtide) + Optimized Background (OB) Versus OB Alone in HIV-1 Infected Patients With Virological Failure.","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2008-01","conditions":"HIV Infections","enrollment":29},{"nctId":"NCT00440271","phase":"PHASE3","title":"SPRING: Safety, Efficacy, Pharmacokinetics of tipRanavir/r IN Race/Gender HIV+ Patients Randomized to TDM or SoC","status":"TERMINATED","sponsor":"Boehringer Ingelheim","startDate":"2007-02","conditions":"HIV Infections","enrollment":33},{"nctId":"NCT00254046","phase":"PHASE3","title":"TMC125-C206: A Phase III Study to Investigate the Efficacy, Tolerability and Safety of TMC125 as Part of an Antiretroviral Regimen, Including TMC114/Ritonavir and an Investigator-selected Optimized Background, in HIV-1 Infected Patients With Limited to no Treatment Options.","status":"COMPLETED","sponsor":"Tibotec Pharmaceuticals, Ireland","startDate":"2005-11","conditions":"HIV","enrollment":616},{"nctId":"NCT00784147","phase":"PHASE2","title":"Dose-Response Study of Ibalizumab (Monoclonal Antibody) Plus Optimized Background Regimen in Patients With HIV-1","status":"COMPLETED","sponsor":"TaiMed Biologics Inc.","startDate":"2008-08","conditions":"HIV","enrollment":113},{"nctId":"NCT00381303","phase":"PHASE3","title":"GRACE: A Study to Compare the Effectiveness, Safety and Tolerability of PREZISTA (Darunavir)/Ritonavir by Gender and Race When Administered With Other Antiretroviral Medications in Human Immunodeficiency Virus (HIV) Positive Women and Men.","status":"COMPLETED","sponsor":"Tibotec, Inc","startDate":"2006-11","conditions":"HIV, Infectious","enrollment":429},{"nctId":"NCT01189695","phase":"PHASE4","title":"Maintenance Boosted Lopinavir Monotherapy Following Salvage Protease-inhibitor (PI) Based Regimen in HIV With Non-nucleoside Reverse Transcriptase Inhibitors (NNRTI) Based Regimen Failure","status":"COMPLETED","sponsor":"Bamrasnaradura Infectious Diseases Institute","startDate":"2010-12","conditions":"HIV, AIDS, Lopinavir","enrollment":63},{"nctId":"NCT00488059","phase":"PHASE4","title":"A Study of Fuzeon (Enfuvirtide) With an Integrase Inhibitor Plus Optimized Background in Treatment-Experienced HIV-1 Infected Patients","status":"TERMINATED","sponsor":"Hoffmann-La Roche","startDate":"2007-06","conditions":"HIV Infections","enrollment":29},{"nctId":"NCT00255099","phase":"PHASE3","title":"TMC125-C216: A Phase III Study to Investigate the Efficacy, Tolerability and Safety of TMC125 as Part of an Antiretroviral Regimen, Including TMC114/Ritonavir and an Investigator-selected Optimized Background, in HIV-1 Infected Patients With Limited to no Treatment Options.","status":"COMPLETED","sponsor":"Tibotec Pharmaceuticals, Ireland","startDate":"2005-12","conditions":"HIV","enrollment":593},{"nctId":"NCT00197197","phase":"PHASE3","title":"Study Of Chemokine Coreceptor 5 (CCR5) Antagonist GW873140 In R5/X4-Tropic Treatment-Experienced HIV-Infected Subjects","status":"TERMINATED","sponsor":"GlaxoSmithKline","startDate":"2005-07","conditions":"HIV Infection","enrollment":18},{"nctId":"NCT00460382","phase":"PHASE2","title":"Clinical Trial to Assess the Efficacy of Darunavir/Ritonavir (DRV/r), Etravirine (ETV) and Raltegravir (MK-0518) in HIV Patients With Resistant Viruses","status":"COMPLETED","sponsor":"French National Agency for Research on AIDS and Viral Hepatitis","startDate":"2007-05","conditions":"HIV Infections","enrollment":103},{"nctId":"NCT01026727","phase":"PHASE2","title":"A Study to Assess the Long-term Efficacy (24 Weeks) of MPC-4326 in Combination With a 2-3 Drug OBR Relative to the Efficacy of a 3-4 Drug ARV Regimen in Treatment Experienced HIV-1 Infected Subjects Who Are Failing Current Antiretroviral Therapy","status":"TERMINATED","sponsor":"Myrexis Inc.","startDate":"2009-11","conditions":"HIV Infections","enrollment":2},{"nctId":"NCT00967187","phase":"PHASE2","title":"Safety and Efficacy Study of MPC-4326 for Treatment of Patients With HIV-1 Infection.","status":"COMPLETED","sponsor":"Myrexis Inc.","startDate":"2008-05","conditions":"HIV Infections","enrollment":32},{"nctId":"NCT00297076","phase":"PHASE3","title":"Chemokine Coreceptor 5 (CCR5) Antagonist GW873140 In R5-Tropic Treatment-Experienced HIV-Infected Subjects","status":"TERMINATED","sponsor":"GlaxoSmithKline","startDate":"2005-07","conditions":"HIV Infection","enrollment":406},{"nctId":"NCT00021554","phase":"PHASE3","title":"T-20 in HIV Patients With Prior Drug Treatment and/or Resistance to Each of the Three Classes of Anti-HIV Drugs","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"","conditions":"HIV Infections","enrollment":525},{"nctId":"NCT00008528","phase":"PHASE3","title":"T-20 With Anti-HIV Combination Therapy for Patients With Prior Anti-HIV Drug Treatment and/or Drug Resistance to Each of the Three Classes of Approved Anti-HIV Drugs","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"","conditions":"HIV Infections","enrollment":525}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":130,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Optimized background therapy (OBT) is chosen on the basis of a subject's resistance test results and treatment history.","OBT","enfuvirtide","antiretroviral therapy","OBR"],"phase":"phase_3","status":"active","brandName":"Optimized Background Regimen","genericName":"Optimized Background Regimen","companyName":"CytoDyn, Inc.","companyId":"cytodyn-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"An optimized antiretroviral background regimen designed to enhance the efficacy of leronlimab (a CCR5 antagonist) in HIV treatment. Used for HIV-1 infection (as background regimen component in clinical trials).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":false,"trials":true,"score":3}}